# A prospective, randomised, double-blinded study to compare bipolar transurethral resection of the prostate (bipolar TURP) versus monopolar transurethral resection of the prostate (monopolar TURP) in terms of safety and efficacy

Submission date 21/07/2006	<b>Recruitment status</b> No longer recruiting	<ul> <li>Prospectively registered</li> <li>Protocol</li> </ul>
<b>Registration date</b> 21/07/2006	<b>Overall study status</b> Completed	<ul> <li>Statistical analysis plan</li> <li>Results</li> </ul>
Last Edited 19/09/2007	<b>Condition category</b> Urological and Genital Diseases	<ul> <li>Individual participant data</li> <li>Record updated in last year</li> </ul>

#### Plain English summary of protocol

Not provided at time of registration

#### **Study website** http://www.turp.nl

## Contact information

**Type(s)** Scientific

**Contact name** Dr S.A. Lagerveld-Zaaijer

#### **Contact details**

Academic Medical Center (AMC) Department of Urology P.O. Box 22660 Amsterdam Netherlands 1100 DD +31 (0)20 5666030 S.A.Zaaijer@amc.uva.nl

## Additional identifiers

EudraCT/CTIS number

**IRAS number** 

ClinicalTrials.gov number

Secondary identifying numbers N/A

## Study information

Scientific Title

**Acronym** TURP

#### Study objectives

Bipolar devices will minimise the disadvantages of the monopolar device such as the risk of electrolyte disturbances by using saline irrigation, bleeding and the risk of nervous stimulation.

**Ethics approval required** Old ethics approval format

**Ethics approval(s)** Not provided at time of registration.

**Study design** A prospective, randomised, double-blinded study

**Primary study design** Interventional

**Secondary study design** Randomised controlled trial

**Study setting(s)** Not specified

**Study type(s)** Treatment

#### Participant information sheet

Health condition(s) or problem(s) studied Benign Prostatic Hyperplasia (BPH)

Interventions

Patients will be randomised into either: Group A: who will undergo a bipolar TURP Group B: who will undergo a monopolar TURP

#### Intervention Type

Other

Phase

Not Specified

#### Primary outcome measure

1. Safety bipolar TURP compared with monoploar TURP by means of transurethral resection (TUR) syndrome

- 2. Blood loss
- 3. Number and severity of adverse events

#### Secondary outcome measures

1. Efficacy of bipolar TURP compared with monopolar TURP by means of IPSS or quality of life (QoL) scores

- 2. International index of erectile function (IIEF) score
- 3. Qmax
- 4. Cutting rate
- 5. Length of catherisation
- 6. Length of hospital stay
- 7. Length of operation
- 8. Impact on prostate specific antigen (PSA) level
- 9. Number of strictures

#### Overall study start date

01/07/2006

#### **Completion date**

31/12/2010

## Eligibility

#### Key inclusion criteria

- 1. Candidates for transurethral resection of the prostate (TURP)
- 2. Qmax less than 16 ml/sec
- 3. International Prostate Symptom Score (IPSS) score greater than 14
- 4. Voided volume greater than 125
- 5. Patients in retention with an indwelling catheter or intermittent catheterisation
- 6. Informed consent

#### **Participant type(s)** Patient

#### **Age group** Adult

**Sex** Both

Target number of participants

94

#### Key exclusion criteria

- 1. If patient is suspected to be suffering from prostate cancer
- 2. Prior prostate surgery, including minimal invasive therapies
- 3. Active urinary tract infection
- 4. Known or suspected neurogenic decompensated bladder (postvoid residual urine volume
- [PVR] greater than 400ml/sec) or compensated detrusor function
- 5. Immunosuppression; using prednisone
- 6. Known or suspected malignant disease affecting the bladder or lower urinary tract
- 7. 5-alpha-reductase inhibitor within the last three months before baseline
- 8. Alpha-blockers within the last six weeks before baseline

9. Specific severe heart disease in whom anti-coagulant therapy might jeopardize treatment outcome

### Date of first enrolment

01/07/2006

# Date of final enrolment 31/12/2010

### Locations

**Countries of recruitment** Netherlands

**Study participating centre Academic Medical Center (AMC)** Amsterdam Netherlands 1100 DD

## Sponsor information

**Organisation** Academic Medical Center (AMC), Department of Urology (The Netherlands)

Sponsor details

P.O. Box 22660 Amsterdam Netherlands 1100 DD

**Sponsor type** University/education

ROR https://ror.org/03t4gr691

## Funder(s)

Funder type Industry

**Funder Name** Karl Storz (UK)

**Funder Name** Academic Medical Center (AMC) (The Netherlands) - Department of Urology

## **Results and Publications**

**Publication and dissemination plan** Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

**IPD sharing plan summary** Not provided at time of registration